A refillable device that releases medicine continuously inside the eye has cleared its most important European hurdle, pushing the bloc closer to a new way of treating one of the leading causes of sight loss in older adults.
The human medicines committee at the European Medicines Agency recommended marketing authorisation for Susvimo, a treatment for adults with neovascular, or wet, age-related macular degeneration. The device is the first refillable ocular implant of its kind to win a positive opinion for the single market, and the file now moves to the European Commission, which is expected to grant the final EU-wide authorisation within weeks.
Wet AMD steals central vision when abnormal blood vessels leak fluid beneath the retina. Standard care leans on repeated injections into the eye, often every month, a schedule many patients struggle to keep. Susvimo takes a different path. Surgeons fix a small implant into the eye, and it drips the drug ranibizumab steadily over months, with clinicians refilling it roughly twice a year.
Trial data underpinning the opinion showed that patients kept vision on par with those receiving monthly injections, and some maintained their sight for years with as few as two treatments annually. The committee limited the recommendation to people whose disease has stabilised after they responded to conventional anti-VEGF injections, framing the implant as a durable option rather than a first line for everyone.
The eye implant was one of twelve medicines the committee endorsed at its July meeting in a busy session that also covered new cholesterol therapies and an updated formula for COVID-19 vaccines targeting the emerging XFG variant. You can read the regulator’s summary in its meeting highlights.
Once the Commission signs off, the authorisation will apply across every member state, though each national health system will decide how quickly it funds the procedure and which clinics can perform the surgery. Ophthalmology centres will need trained teams and follow-up systems before patients see the benefit in practice.
Cost and capacity will shape how much difference the decision makes. A continuous-delivery implant demands operating-theatre time, trained surgeons and careful monitoring for rare complications, so health systems will weigh the upfront burden against fewer clinic visits later. Analysts expect uptake to build gradually as centres gain experience with the device.
The manufacturer set out the clinical case in its own announcement, and campaigners for older patients welcomed a design that could cut the number of clinic visits. For an ageing continent facing rising rates of vision loss, a treatment that trades monthly needles for two refills a year could ease pressure on eye services as much as it helps individual patients.
